1,3,5-Triazine-2,4-diamine, 1,6-dihydro-6,6-dimethyl-1-(4-(4-phenylbutyl)phenyl)- | 24892-90-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: 1,3,5-Triazine-2,4-diamine, 1,6-dihydro-6,6-dimethyl-1-(4-(4-phenylbutyl)phenyl)-
• 英文别名: 6,6-dimethyl-1-[4-(4-phenylbutyl)phenyl]-1,3,5-triazine-2,4-diamine
• CAS: 24892-90-8
• 化学式: C₂₁H₂₇N₅
• 分子量: 349.5
• InChiKey: RHDNKXYQUZIPEI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  80
• 氢给体数：
  2
• 氢受体数：
  1

文献信息

• Therapeutic compositions and methods of making and using the same
  申请人：Advanced ReGen Medical Technologies, LLC

  公开号：US10717981B2

  公开（公告）日：2020-07-21

  Disclosed herein are polynucleotide agents (including interfering RNA agents (RNAi)), small molecule agents, and synthetic cells, methods of making the same, and their use as therapeutics against age-related dysfunction and/or cellular dysfunction that results in various disease states. In some embodiments, one or more agents as disclosed herein can be used to target and/or decrease the expression of the paired-box protein 5 (PAX5) gene, protein phosphatase, Mg2+/Mn2+ dependent 1F (PPM1F) gene, or both. Also disclosed herein are methods for the preparation and use of synthetic cells prepared by in vitro and/or in vivo manipulation using one or more cellular factors, polynucleotide agents, and/or small molecule agents. Disclosed herein is the use of these cells as therapeutic cells that treat age-related dysfunction and/or cellular dysfunction resulting in various disease states.

  本文公开了多核苷酸制剂（包括干扰 RNA 制剂 (RNAi)）、小分子制剂和合成细胞、制作方法，以及它们作为治疗与年龄相关的功能障碍和/或导致各种疾病状态的细胞功能障碍的用途。在一些实施方案中，本文公开的一种或多种制剂可用于靶向和/或降低配对盒蛋白 5（PAX5）基因、蛋白磷酸酶、Mg2+/Mn2+依赖性 1F（PPM1F）基因或两者的表达。本文还公开了利用一种或多种细胞因子、多核苷酸制剂和/或小分子制剂，通过体外和/或体内操作制备和使用合成细胞的方法。本文公开了这些细胞作为治疗细胞的用途，可治疗与年龄有关的功能障碍和/或导致各种疾病状态的细胞功能障碍。
• GLYCINE, MITOCHONDRIAL ONE-CARBON METABOLISM, AND CANCER
  申请人：The General Hospital Corporation

  公开号：EP2971153A1

  公开（公告）日：2016-01-20
• Glycine, Mitochondrial One-Carbon Metabolism, and Cancer
  申请人：THE GENERAL HOSPITAL CORPORATION

  公开号：US20160032401A1

  公开（公告）日：2016-02-04

  Methods of treatment, diagnosis, and determining prognosis of subjects with cancer, generally comprising determining levels of glycine metabolism or a mitochondrial 1-carbon (1-C) pathway enzyme, e.g., SHMT2, MTHFD1L, or MTHFD2, and optionally administering an antifolate or an agent that inhibits a mitochondrial 1-carbon (1-C) pathway enzyme, e.g., SHMT2 or MTHFD2.
• THERAPEUTIC COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
  申请人：Advanced ReGen Medical Technologies, LLC

  公开号：US20190218558A1

  公开（公告）日：2019-07-18

  Disclosed herein are polynucleotide agents (including interfering RNA agents (RNAi)), small molecule agents, and synthetic cells, methods of making the same, and their use as therapeutics against age-related dysfunction and/or cellular dysfunction that results in various disease states. In some embodiments, one or more agents as disclosed herein can be used to target and/or decrease the expression of the paired-box protein 5 (PAX5) gene, protein phosphatase, Mg 2+ /Mn 2+ dependent 1F (PPM1F) gene, or both. Also disclosed herein are methods for the preparation and use of synthetic cells prepared by in vitro and/or in vivo manipulation using one or more cellular factors, polynucleotide agents, and/or small molecule agents. Disclosed herein is the use of these cells as therapeutic cells that treat age-related dysfunction and/or cellular dysfunction resulting in various disease states.
• METHODS AND CLINICAL PROTOCOLS AND KITS PERTAINING TO MAKING AND USING THERAPEUTIC COMPOSITIONS FOR CELLULAR TREATMENT
  申请人：ADVANCED REGEN MEDICAL TECHNOLOGIES, LLC

  公开号：US20220220561A1

  公开（公告）日：2022-07-14

  Disclosed herein are methods for preparing clinically useable target cells for use in achieving a clinical effect in patients. The protocols disclosed herein have been shown to improve cell yield during collection of target cells, transport of target cells, storage of target cells, and use of target cells. Also disclosed herein are kits and methods for testing patients and preparing clinically useable target cells for use in achieving a clinical effect in patients. The kits and protocols therein improve cell yield during collection of target cells, transport of target cells, storage of target cells, and use of target cells.